Penumbra targets 13%-14% revenue growth for 2025 with focus on thrombectomy market expansion
Q4 2024 Management View CEO Adam Elsesser highlighted revenue of $321.3 million for Q4 2024, representing a year-over-year growth of 12.9% on an adjusted basis, driven by strong performance in the U.S ...
Burcon NutraScience targets cash flow positive in 2026 with new production facility
Q3 2025 Management View CEO Kip Underwood highlighted the successful completion of a $9.4M rights offering, a turnkey agreement with ProMan to purchase a U.S.-based production facility, and the launch ...